Clinical Trial Update: Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of divalproex sodium 125 mg delayed-release tablets under fasting conditions conducted by Sandoz.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Divalproex Sodium 125 mg Delayed Release Tablets (divalproex sodium)

Snippet

Sponsor: Sandoz | Conditions: Seizures | Phase 1 | Status: COMPLETED